| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL PAPER |
Department of Medical Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia
Michael Friedlander, M.D., Department of Medical Oncology, Prince of Wales Hospital, High Street Randwick NSW 2031, Australia. Telephone: 612-9382-2606; Fax: 612-9382-2588; e-mail: m.friedlander{at}unsw.edu.au
Although there have been important advances in the management of women with cervical cancer, the optimal treatment for patients with locally recurrent and metastatic disease is still problematic, and there are relatively few randomized trials to guide treatment decisions. This paper reviews the approach to management of patients who relapse after primary treatment for cervical cancer. Patients who are still potentially curable with radical treatment are identified, and the various treatment strategies are discussed. However, most women are treated with palliative intent, and the literature on palliative management is reviewed together with the levels of evidence.
This article has been cited by other articles:
![]() |
N. Reesink-Peters, J. van der Velden, K. A. ten Hoor, H. M. Boezen, E. G.E. de Vries, M. S. Schilthuis, M. J.E. Mourits, H. W. Nijman, J. G. Aalders, H. Hollema, et al. Preoperative Serum Squamous Cell Carcinoma Antigen Levels in Clinical Decision Making for Patients With Early-Stage Cervical Cancer J. Clin. Oncol., March 1, 2005; 23(7): 1455 - 1462. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |